NCT05330910Recruiting
Crural Repair During Laparoscopic Sleeve Gastrectomy in Patients With a Lax Gastroesophageal Junction
A Randomized Controlled Trial Evaluating PAtients With Lax Gastroesophageal Junction to Initial Sleeve Gastrectomy With or Without Concomitant Crural Repair (REPAIR)
Source: ClinicalTrials.gov · Last updated 15 Apr 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Background: Laparoscopic sleeve gastrectomy (LSG) is one of the commonest bariatric procedures. However, it is associated with postoperative gastroesophageal reflux disease (GERD) and erosive esophagitis (EE). The investigators' preliminary study suggests that the incidence of postoperative GERD and EE appears to be correlated with the preoperative presence of a lax gastroesophageal flap valve and hiatal hernia. Hypothesis/ Aim: To investigate the impact of a concomitant hiatal hernia repair with LSG on the incidence of postoperative EE. Significance: For patients with pre-existing EE, most surgeons will recommend a laparoscopic Roux-en-Y gastric bypass (LRYGB) as their primary bariatric procedure. However, compared to LSG, LRYGB is a technically more demanding procedure with increased morbidity and long term nutritional deficiencies. For asymptomatic patients at risk of postoperative EE due to presence of a hiatal hernia, there is still no consensus on the most appropriate bariatric surgical option. A LSG with a concomitant hiatal hernia repair, if shown to reduce EE postoperatively, may help to expand the pool of patients suitable for LSG in the future. Methods: A two center, double-blinded, randomized controlled trial of all patients, undergoing LSG with a preoperative diagnosis of a Hill's grade III gastroesophageal junction, will be randomized to having a concomitant hiatal hernia repair (experimental arm) versus just LSG alone (control arm). Primary outcome measures include 1-year postoperative EE on endoscopy. Secondary outcome measures include postoperative morbidity, blood loss, quality of life and GERD symptoms at 1-year postoperatively.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 27 Mar 2022
- Start date
- 1 Apr 2022
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Sengkang General Hospital
- Diseases
- Obesity
- NCT number
- NCT05330910
What you commit to
- Study type: Interventional
- Planned participants: 96
- From 1 Apr 2022 to the primary completion date, 30 Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Had previous upper gastrointestinal surgery
Other
- Unable or unwilling to provide informed consent
- Contraindications to laparoscopic sleeve gastrectomy
- Opted not to undergo laparoscopic sleeve gastrectomy
- Had documented erosive esophagitis on preoperative endoscopy
- Had Hill's grade I, II or IV gastroesophageal junction on preoperative endoscopy
Who the study is looking for
- 21-65 years old
- Able to provide informed consent
- Hill's grade III gastroesophageal junction on preoperative endoscopy
- Opted to undergo laparoscopic sleeve gastrectomy as their bariatric procedure
Age in the registry: 21 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sengkang General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.